Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,346.00+0.85%ETH$2,420.07+0.87%GOLD$4,327.00-1.38%OIL$101.32-1.08%
Smart Investors Daily
AL

NASDAQ · ALXO

ALX Oncology Holdings Inc.

Healthcare · Biotechnology

$1.76

Down-$0.13 (-6.88%)

Updated Sep 17, 2026, 6:24 AM

SID Score

4.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
114.42M
P/E ratio
-1.13
Dividend yield
0.00%
52-week range
$1.37 – $2.41
Volume
821.21K
Avg. volume
511.22K

Price performance

ALXO price history

1M range · 0 trading sessions · Daily adjusted prices

ALXO does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ALXO news

The latest Smart Investors Daily articles mentioning ALXO.

Stock researchCompany · Overview

ALXO research

Overview

Company profile and research snapshot.

Company profile

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$21.38
Implied upside
—
Analysts
11
ALXO recent ratings
DateFirmRatingTarget
Mar 19, 2026Wells FargoOverweight—
Mar 10, 2026HC Wainwright & Co.Buy—
Feb 5, 2026Piper SandlerOverweight—
May 21, 2025UBSBuy—
May 9, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

ALX Oncology to Present at Upcoming Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in fireside chats at three upcoming investor conferences. The details of the meetings are as follows: Wells Fargo 21st Annual Healthcare Conference Format: Fireside Chat and One-on-on

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By